Research programme:anti-infective therapeutics - AiCuris/Ligand Pharmaceuticals

Drug Profile

Research programme:anti-infective therapeutics - AiCuris/Ligand Pharmaceuticals

Alternative Names: AIC 499

Latest Information Update: 06 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AiCuris; Ligand Pharmaceuticals
  • Class Antibacterials
  • Mechanism of Action Beta lactamase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acinetobacter infections; Pseudomonal infections
  • Research Gram-negative infections

Most Recent Events

  • 06 Sep 2016 Early research in Gram-negative infections in USA before September 2016 (AiCuris pipeline, September 2016)
  • 06 Aug 2015 Ligand Pharmaceuticals and Aicuris agree to co-develop anti-infective therapeutics in USA for Infections
  • 06 Aug 2015 Preclinical trials in Acinetobacter infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top